拓扑替康|T5784

Topotecan
123948-87-8

￥143 2mg 起订

￥209 5mg 起订

￥417 10mg 起订

上海更新日期：2024-09-14

TargetMol中国（陶术生物）

VIP12年

联系人：邵小姐

电话：021-021-33632979拨打

手机：15002134094 拨打

邮箱：marketing@targetmol.com

产品详情:

中文名称：: 拓扑替康

英文名称：: Topotecan

CAS号：: 123948-87-8

品牌：: TargetMol

产地：: 美国

保存条件：: keep away from direct sunlight,keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.

纯度规格：: 95.19%

产品类别：: 抑制剂

货号：: T5784

Product Introduction

Bioactivity

Name	Topotecan
Description	Topotecan (NSC-609669) is a Topoisomerase I inhibitor,and is an antineoplastic agent used to treat ovarian cancer that works by inhibiting DNA topoisomerases.
Cell Research	After isolated and identified the GSCs from glioma cells successfully, U251, U87, GSCs-U251 and GSCs-U87 cells were administrated with various concentrations of shikonin or topotecan at different time points to seek for the optimal administration concentration and time point.?The cell viability, cell cycle and apoptosis were detected using cell counting kit-8 and flow cytometer to observe the inhibitory effects on glioma cells and GSCs[1].
Animal Research	Hydrogel cytotoxicity was evaluated in retinoblastoma cells as a surrogate for efficacy and Topotecan vitreous pharmacokinetics and systemic as well as ocular toxicity were evaluated in rabbits. The pseudoplastic behavior of the hydrogels makes them suitable for intraocular administration. In vitro release profiles showed a sustained release of Topotecan from PCL-PEG-PCL up to 7days and drug loading did not affect the release pattern. Blank hydrogels did not affect retinoblastoma cell viability but 0.4% (w/w) Topotecan-loaded hydrogel was highly cytotoxic for at least 7days. After intravitreal injection, Topotecan vitreous concentrations were sustained above the pharmacologically active concentration. One month after injection, animals with blank or Topotecan-loaded hydrogels showed no systemic toxicity or retinal impairment on fundus examination, electroretinographic, and histopathological assessments[2].
In vitro	Topoisomerase I抑制剂，topotecan，通过抑制生长及诱导GSCs和胶质瘤细胞的凋亡，表明它们可能是针对胶质瘤的潜在抗癌化合物，为提供新的治疗策略提供了可能性[1]。
In vivo	Topotecan-水凝胶能够向玻璃体持续输送活性药物，具有优良的体内生物相容性以及在视网膜母细胞瘤细胞中明显的细胞毒作用，可能成为眼内视网膜母细胞瘤治疗的一个补充策略[2]。
Storage	keep away from direct sunlight,keep away from moisture \| Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
Solubility Information	DMSO : 84 mg/mL (199.31 mM)
Keywords	U87 \| U251 \| Topotecan \| Topoisomerase \| orally active \| NSC-609669 \| NSC609669 \| Inhibitor \| inhibit \| GSCs-U87 \| GSCs-U251 \| Autophagy
Inhibitors Related	Guanidine hydrochloride \| Naringin \| Valproic Acid \| Taurine \| Gefitinib \| Aceglutamide \| Hydroxychloroquine \| Curcumin \| Stavudine \| Salicylic acid \| Paeonol \| Sodium 4-phenylbutyrate
Related Compound Libraries	Inhibitor Library \| Bioactive Compound Library \| Anti-Cancer Active Compound Library \| Anti-Cancer Approved Drug Library \| Selected Plant-Sourced Compound Library \| EMA Approved Drug Library \| Anti-Aging Compound Library \| Anti-Tumor Natural Product Library \| Natural Product Library \| Drug Repurposing Compound Library \| Anti-Cancer Clinical Compound Library \| Natural Product Library for HTS

拓扑替康|||SKF 104864A|||NSC 609669|TargetMol

上海陶术生物科技有限公司为美国Target Molecule Corp. ( Target Mol ) 在上海建立的全资子公司。我们与美国波士顿、德国慕尼黑的同事一起，为北美、欧洲和亚洲从事药物研发和生物学研究的科学家提供优质的产品和专业的服务。公司下设筛选事业部，化学事业部，生物事业部和新材料部。从虚拟筛选到实体化合物分子供应；从商业化产品销售到个性化定制合成；从对明确靶点的分子筛选到对明确分子的多靶点筛选，从高通量筛选到化学结构优化，我们都可以满足您的科研用品及技术服务的需求。经过在中国市场五年的精心耕耘，我们已成为筛选化合物领域优秀的供应商，为超过五百家学校和各类企业提供了品质卓越的小分子化合物和药物筛

成立日期	(12年)
注册资本	566.2651万人民币
员工人数	100-500人
年营业额	￥ 1亿以上
经营模式	贸易,试剂,定制,服务
主营行业	化学试剂,生物活性小分子